Tuesday, July 23, 2019
ProMIS Neurosciences (PMN:CA)
Amid Skepticism, Light Will Emerge in Alzheimer’s Area
ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).
Cosme Ordonez, MD, Ph.D., Senior Life Sciences Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- ProMIS showcases its technology at Medical Conference. At the Annual Alzheimer’s Association International Conference (AAIC) held in Los Angeles last week, Dr. Johanne Kaplan, the company’s Chief Development Officer, made an oral presentation on the therapeutic potential of candidate drug PMN310 for the treatment of Alzheimer’s disease (AD).
- Despite current skepticism, there is still hope. In recent months, negative news released by…
Get full report on Channelchek desktop.
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.